about
Identification of HDAC6-Selective Inhibitors of Low Cancer Cell CytotoxicityBicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth DiseaseWhy Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells.Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models.Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.Synthesis and structure-activity relationships of boswellic acid derivatives as potent VEGFR-2 inhibitors.Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X SyndromeA Remarkable Difference That One Fluorine Atom Confers on the Mechanisms of Inactivation of Human Ornithine Aminotransferase by Two Cyclohexene Analogues of γ-Aminobutyric AcidHDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in miceDiscovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted MorpholinopyrimidinesMolecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide InhibitorA patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse ModelsDesign of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT2C) receptor agonist without 5-HT2B agonism
P50
Q30366109-23AE0748-C765-4D91-8895-3F071F057340Q35849793-E114AF61-5B86-4DA6-85D1-EB0DC6160E58Q36614119-FE07539B-0E11-4FF8-AA20-7856917634F8Q39262864-5E17C50C-6592-46A3-9F0D-30A589282136Q50066085-390B24C2-E468-4856-BE65-086401827332Q52657524-2541339A-D90C-41E2-B590-D18F36E0DC67Q54281232-2BBA58A4-F85C-44FF-9CC7-6815AA79D5F9Q64042313-A872CDC1-A334-42D3-A71D-3308B013B1F9Q89958278-E1178451-BEA4-4A3C-87F1-C889B6B15EEAQ90138433-9F092054-81E8-4C67-BF58-DB5D2FBC0474Q90402998-A9B78E17-824E-4A92-8279-393E5C8A10C3Q90910603-1B383693-810B-4E40-B89C-F9932F2DF675Q92181536-6600E3F7-AED2-4557-A5D1-B46605B629E7Q92634159-C51C2B8C-4963-465E-B4A5-BF7B5A13D90BQ92840145-D4B8998C-FE4D-45F2-A405-58C464FBC08C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sida Shen
@ast
Sida Shen
@en
Sida Shen
@es
Sida Shen
@nl
type
label
Sida Shen
@ast
Sida Shen
@en
Sida Shen
@es
Sida Shen
@nl
prefLabel
Sida Shen
@ast
Sida Shen
@en
Sida Shen
@es
Sida Shen
@nl
P106
P31
P496
0000-0002-0295-2545